Ernexa Therapeutics Inc. (NASDAQ:ERNA) Sees Significant Decrease in Short Interest

Ernexa Therapeutics Inc. (NASDAQ:ERNA) saw a large decrease in short interest in October. As of October 15th, there was short interest totaling 39,600 shares, a decrease of 28.6% from the September 30th total of 55,500 shares. Based on an average daily trading volume, of 94,700 shares, the short-interest ratio is presently 0.4 days. Currently, 1.3% of the company’s stock are sold short. Currently, 1.3% of the company’s stock are sold short. Based on an average daily trading volume, of 94,700 shares, the short-interest ratio is presently 0.4 days.

Ernexa Therapeutics Stock Performance

Shares of ERNA stock opened at $1.68 on Wednesday. The stock’s 50-day simple moving average is $1.30 and its 200-day simple moving average is $2.01. The firm has a market capitalization of $12.89 million, a PE ratio of -0.02 and a beta of 5.72. Ernexa Therapeutics has a fifty-two week low of $1.09 and a fifty-two week high of $18.00.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.61) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Ernexa Therapeutics presently has an average rating of “Sell”.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.